Investors can speculate about the future of a stock by watching how its insiders buy and sell stocks. Apogee Therapeutics Inc shares valued at $817,500 were sold by Dambkowski Carl on Dec 04 ’25. At $75.00 per share, Dambkowski Carl sold 10,900 shares. The insider’s holdings dropped to 271,108 shares worth approximately $20.75 million following the completion of this transaction.
Also, Henderson Jane sold 1,500 shares, netting a total of over 112,500 in proceeds. Following the sale of shares at $75.00 each, the insider now holds 194,871 shares.
Before that, HENDERSON MICHAEL THOMAS had sold 40,000 shares from its account. In a trade valued at $3,000,400, the Chief Executive Officer traded Apogee Therapeutics Inc shares for $75.01 each. Upon closing the transaction, the insider’s holdings decreased to 40,000 shares, worth approximately $94.36 million.
As published in their initiating research note from Deutsche Bank on December 10, 2025, Apogee Therapeutics Inc [APGE] has been a Buy and the price target has been revised to $103. Analysts at Craig Hallum started covering the stock with ‘”a Buy”‘ outlook in a report released in early November. As of October 21, 2025, Mizuho has initiated its “an Outperform” rating for APGE. Earlier on September 25, 2025, RBC Capital Mkts initiated its rating. Their recommendation was “an Outperform” for APGE stock.
Analyzing APGE Stock Performance
On last trading session, Apogee Therapeutics Inc [NASDAQ: APGE] rose 0.62% to $76.53. The stock’s lowest price that day was $75.33, but it reached a high of $77.68 in the same session. During the last five days, there has been a surge of approximately 1.36%. Over the course of the year, Apogee Therapeutics Inc shares have jumped approximately 55.96%. Shares of the company reached a 52-week high of $77.93 on 12/11/25 and a 52-week low of $26.20 on 04/08/25.
Support And Resistance Levels for Apogee Therapeutics Inc (APGE)
According to the 24-hour chart, there is a support level at 75.26, which, if violated, would cause prices to drop to 74.00. In the upper region, resistance lies at 77.86. The next price resistance is at 79.20. RSI (Relative Strength Index) is 73.06 on the 14-day chart, showing overbought technical sentiment.
Is Apogee Therapeutics Inc subject to short interest?
Stocks of Apogee Therapeutics Inc saw a sharp steep in short interest on 2025-11-28 dropping by 55782.0 shares to 7.9 million. Data from Yahoo Finance shows that the short interest on 2025-10-31 was 7.95 million shares. A decline of -0.71% in short interest reflects a positive sentiment towards the stock. Despite the fact that short shares comprise just 11.26 of the overall float, the days-to-cover ratio (short ratio) decline to 11.26.
Which companies own the most shares of Apogee Therapeutics Inc (APGE)?
In terms of Apogee Therapeutics Inc share price expectations, FactSet research, analysts set an average price target of 103 in the next 12 months, up nearly 35.42% from the previous closing price of $76.06. Analysts anticipate Apogee Therapeutics Inc stock to reach 109 by 2025, with the lowest price target being 60. On July 07, 2025, BTIG Research assigned a price target of “a Buy” to the stock and reiterated coverage with a $115.